Metabolic diseases are important risk factors for the development of heart failure, and energetic deficit and oxidative stress are important in its pathophysiology. A Focus issue in Nature Reviews Cardiology appraises the metabolic alterations in heart failure, with an emphasis on substrate and intermediate metabolism, vascular dysfunction, inflammation and mechano-energetic uncoupling, integrating these different pathomechanistic angles into one cohesive view.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Groenewegen, A., Rutten, F. H., Mosterd, A. & Hoes, A. W. Epidemiology of heart failure. Eur. J. Heart Fail. 22, 1342–1356 (2020).
Neubauer, S. The failing heart—an engine out of fuel. N. Engl. J. Med. 356, 1140–1151 (2007).
Bertero, E. & Maack, C. Metabolic remodelling in heart failure. Nat. Rev. Cardiol. 15, 457–470 (2018).
Bertero, E. & Maack, C. Calcium signaling and reactive oxygen species in mitochondria. Circ. Res. 122, 1460–1478 (2018).
Cannata, A. & McDonagh, T. A. Heart failure with preserved ejection fraction. N. Engl. J. Med. 392, 173–184 (2025).
Maack, C., Vilahur, G., Ruiz-Meana, M. & Hausenloy, D. New COST Action ‘EUropean network to tackle METAbolic alterations in HEART failure’ (EU-METAHEART). Eur. Heart J. 45, 4460–4463 (2024).
Mericskay, M. et al. Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-025-01166-7 (2025).
Liberale, L. et al. Vascular (dys)function in the failing heart. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-025-01163-w (2025).
Andreadou, I. et al. Immunometabolism in heart failure. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-025-01165-8 (2025).
Aksentijevic, D. et al. Mechano-energetic uncoupling in heart failure. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-025-01167-6 (2025).
Paulus, W. J. & Tschöpe, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263–271 (2013).
Vilahur, G., Kleinbongard, P., Zuurbier, C. J. & Core Group of the COST Action EU-METAHEART (CA22169). In memoriam: Ioanna Andreadou (1965–2025). Eur. Heart J. 46, 1699–1701 (2025).
Lopaschuk, G. D. et al. Cardiac energy metabolism in heart failure. Circ. Res. 128, 1487–1513 (2021).
Dyck, J. R. B. In memory of Dr Gary D. Lopaschuk, PhD (1955–2025). JACC Basic Transl. Sci 10, 704–705 (2025).
Acknowledgements
The article was written on behalf of the core group of COST Action EU-METAHEART (CA22169). All EU-METAHEART members are listed in the Supplementary Information. C.M. is funded by the DFG (SFB-1525/project No. 453989101 and Ma: 2528/8-1) and the German Center for Cardiovascular Research (DZHK; EX-22 and FKZ 81X2800227).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.M. is an advisory board member or speaker for Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Lilly, Novartis, Novo Nordisk and Servier.
Additional information
Related links
COST Action CA22169: https://www.cost.eu/actions/CA22169/
EU-METAHEART: https://cost-metaheart.eu/
Supplementary information
Rights and permissions
About this article
Cite this article
Maack, C. Metabolic alterations in heart failure. Nat Rev Cardiol 22, 695–696 (2025). https://doi.org/10.1038/s41569-025-01181-8
Published:
Issue date:
DOI: https://doi.org/10.1038/s41569-025-01181-8
